Cargando…
Design and Evaluation of Voriconazole Eye Drops for the Treatment of Fungal Keratitis
Voriconazole is a novel antifungal agent with excellent broad spectrum activity commercially available for oral and intravenous administration. The purpose of this study was to prepare ophthalmic formulation of hydroxypropyl beta cyclodextrin (HP-β-CD) based voriconazole containing benzalkonium chlo...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4590801/ https://www.ncbi.nlm.nih.gov/pubmed/26556196 http://dx.doi.org/10.1155/2014/490595 |
_version_ | 1782392982505259008 |
---|---|
author | Malhotra, Sakshi Khare, Anubha Grover, Kanchan Singh, Inderbir Pawar, Pravin |
author_facet | Malhotra, Sakshi Khare, Anubha Grover, Kanchan Singh, Inderbir Pawar, Pravin |
author_sort | Malhotra, Sakshi |
collection | PubMed |
description | Voriconazole is a novel antifungal agent with excellent broad spectrum activity commercially available for oral and intravenous administration. The purpose of this study was to prepare ophthalmic formulation of hydroxypropyl beta cyclodextrin (HP-β-CD) based voriconazole containing benzalkonium chloride BAK and EDTA with or without viscosity modifiers and study its permeation characteristics through freshly excised goat cornea. The results were observed that viscosity and force of bioadhesion of the voriconazole HP-β-CD solutions containing xanthan gum (XG) are more as compared to polyvinyl alcohol. The results revealed that voriconazole drop containing PVA provided least viscosity and higher corneal permeation of drug, while drop formulated with XG had maximum viscosity and least permeation. The HP-β-CD based voriconazole (1.5%) ophthalmic formulation containing xanthan gum (1.5), preserved with BAK and EDTA, could provide shelf life of 2 years. The microbiological studies showed that voriconazole ophthalmic solution containing xanthan gum shows better antifungal activity as compared to voriconazole and xanthan gum alone. Thus, it can be concluded that HP-β-CD based voriconazole (1.5%, pH 7.0) ophthalmic solution containing BAK and EDTA with viscosity modifier XG provided maximum precorneal residence time as compared to other viscosity modifiers and polyvinyl alcohol provided less precorneal residence time than other viscosity modifiers. |
format | Online Article Text |
id | pubmed-4590801 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-45908012015-10-13 Design and Evaluation of Voriconazole Eye Drops for the Treatment of Fungal Keratitis Malhotra, Sakshi Khare, Anubha Grover, Kanchan Singh, Inderbir Pawar, Pravin J Pharm (Cairo) Research Article Voriconazole is a novel antifungal agent with excellent broad spectrum activity commercially available for oral and intravenous administration. The purpose of this study was to prepare ophthalmic formulation of hydroxypropyl beta cyclodextrin (HP-β-CD) based voriconazole containing benzalkonium chloride BAK and EDTA with or without viscosity modifiers and study its permeation characteristics through freshly excised goat cornea. The results were observed that viscosity and force of bioadhesion of the voriconazole HP-β-CD solutions containing xanthan gum (XG) are more as compared to polyvinyl alcohol. The results revealed that voriconazole drop containing PVA provided least viscosity and higher corneal permeation of drug, while drop formulated with XG had maximum viscosity and least permeation. The HP-β-CD based voriconazole (1.5%) ophthalmic formulation containing xanthan gum (1.5), preserved with BAK and EDTA, could provide shelf life of 2 years. The microbiological studies showed that voriconazole ophthalmic solution containing xanthan gum shows better antifungal activity as compared to voriconazole and xanthan gum alone. Thus, it can be concluded that HP-β-CD based voriconazole (1.5%, pH 7.0) ophthalmic solution containing BAK and EDTA with viscosity modifier XG provided maximum precorneal residence time as compared to other viscosity modifiers and polyvinyl alcohol provided less precorneal residence time than other viscosity modifiers. Hindawi Publishing Corporation 2014 2014-04-29 /pmc/articles/PMC4590801/ /pubmed/26556196 http://dx.doi.org/10.1155/2014/490595 Text en Copyright © 2014 Sakshi Malhotra et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Malhotra, Sakshi Khare, Anubha Grover, Kanchan Singh, Inderbir Pawar, Pravin Design and Evaluation of Voriconazole Eye Drops for the Treatment of Fungal Keratitis |
title | Design and Evaluation of Voriconazole Eye Drops for the Treatment of Fungal Keratitis |
title_full | Design and Evaluation of Voriconazole Eye Drops for the Treatment of Fungal Keratitis |
title_fullStr | Design and Evaluation of Voriconazole Eye Drops for the Treatment of Fungal Keratitis |
title_full_unstemmed | Design and Evaluation of Voriconazole Eye Drops for the Treatment of Fungal Keratitis |
title_short | Design and Evaluation of Voriconazole Eye Drops for the Treatment of Fungal Keratitis |
title_sort | design and evaluation of voriconazole eye drops for the treatment of fungal keratitis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4590801/ https://www.ncbi.nlm.nih.gov/pubmed/26556196 http://dx.doi.org/10.1155/2014/490595 |
work_keys_str_mv | AT malhotrasakshi designandevaluationofvoriconazoleeyedropsforthetreatmentoffungalkeratitis AT khareanubha designandevaluationofvoriconazoleeyedropsforthetreatmentoffungalkeratitis AT groverkanchan designandevaluationofvoriconazoleeyedropsforthetreatmentoffungalkeratitis AT singhinderbir designandevaluationofvoriconazoleeyedropsforthetreatmentoffungalkeratitis AT pawarpravin designandevaluationofvoriconazoleeyedropsforthetreatmentoffungalkeratitis |